V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310008011 | 310008260 | 1.87 | null | Curative (C) | 2018-07-10 | 2018-07-10 | Gemcitabine + Oxaliplatin | N | N | 310023255 | ERLOTINIB |
| 310008012 | 310008260 | 1.6 | 92.7 | Curative (C) | 2017-07-10 | 2017-07-18 | FLAG + Idarubicin | N | N | 310023255 | TEMOZOLOMIDE |
| 310008013 | 310008261 | 1.85 | 66 | Palliative (P) | 2014-05-31 | 2014-06-27 | RUXOLITINIB | N | N | 310023298 | OXALIPLATIN + MDG |
| 310008014 | 310005168 | 1.84 | 7.3 | Palliative (P) | 2018-04-29 | 2018-05-02 | Gemcitabine + Vinorelbine IV | N | N | 310023303 | CYTARABINE HD + METHOTREXATE HD |
| 310008015 | 310005168 | 0 | 74.4 | Curative (C) | 2013-10-16 | 2013-10-18 | CARMUSTINE + THIOTEPA | N | null | 310023303 | NIVOLUMAB |
| 310008016 | 310009906 | 1.7 | 59 | Adjuvant (A) | 2015-11-02 | 2016-02-01 | IVADo | N | N | 310023373 | IVE + METHOTREXATE |
| 310008017 | 310005169 | 1.63 | 55 | Palliative (P) | 2016-05-04 | 2016-05-06 | OCTOPUS Trial | N | N | 310023378 | DABRAFENIB |
| 310008018 | 310005170 | 1.77 | 110.6 | Palliative (P) | 2015-05-06 | 2015-05-08 | ICON8B TRIAL | N | N | 310023391 | DOXORUBICIN |
| 310008021 | 310005173 | null | 0 | Palliative (P) | 2016-07-09 | 2016-08-07 | CTD Attenuated (Thalidomide 50mg) | N | N | 310023407 | DHAP - R |
| 310008022 | 310005175 | 0 | 63 | Curative (C) | 2016-03-02 | 2016-03-02 | Mitotane 3 - 3.5g | N | N | 310023414 | BCG |
| 310008023 | 310008266 | 1.73 | null | null | 2014-05-29 | 2014-06-03 | Oxaliplatin + Modified de Gramont | N | N | 310023426 | TEMOZOLOMIDE |
| 310008024 | 310005177 | 1.32 | 0 | Curative (C) | 2015-08-07 | 2015-08-16 | IPO | N | N | 310023468 | CAPECITABINE + OXALIPLATIN |
| 310008025 | 310005178 | 1.83 | null | Curative (C) | 2016-11-14 | 2016-11-14 | Cisplatin + Fluorouracil + RT 5day | N | N | 310023468 | BORTEZOMIB |
| 310008026 | 310005179 | 1.73 | 76.3 | Disease modification (D) | 2018-09-29 | 2018-10-24 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | N | N | 310023489 | CARBOPLATIN + DOCETAXEL |
| 310008027 | 310005179 | 1.8 | 61 | Adjuvant (A) | 2015-06-05 | 2015-06-15 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 2 | N | 310023489 | CYCLO + ETOPOSIDE + NELARABINE |
| 310008028 | 310008269 | 1.61 | 67.4 | Palliative (P) | 2017-02-22 | 2017-04-13 | Olaparib | 02 | N | 310023496 | TRABECTEDIN |
| 310008029 | 310008269 | 1.68 | 42.2 | Palliative (P) | 2015-11-09 | 2015-11-12 | MITOMYCIN | N | N | 310023496 | TRASTUZUMAB |
| 310008030 | 310008269 | 1.58 | null | Palliative (P) | 2014-06-13 | 2014-07-26 | IGEV | N | N | 310023496 | LANREOTIDE |
| 310008031 | 310008269 | 1.75 | null | Neo-adjuvant (N) | 2014-09-02 | 2014-09-30 | BCG Intravesical | N | N | 310023496 | CAV |
| 310008032 | 310005183 | 1.72 | 98 | Curative (C) | 2016-08-13 | 2016-08-18 | ECHELON-2 TRIAL | N | N | 310023518 | CISPLATIN + ETOPOSIDE |
| 310008033 | 310005183 | 1.78 | 68.5 | Disease modification (D) | 2017-04-20 | 2017-09-08 | CAPECITABINE + CARBOPLATIN | 02 | N | 310023518 | LENALIDOMIDE |
| 310008034 | 310005187 | 1.44 | 52.5 | Palliative (P) | 2016-09-16 | 2016-11-02 | Capecitabine | N | N | 310023544 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310008035 | 310005188 | 1.55 | 90 | Palliative (P) | 2015-11-27 | 2017-02-23 | Capecitabine | N | N | 310023544 | IPILIMUMAB + NIVOLUMAB |
| 310008036 | 310005188 | 0 | null | Palliative (P) | 2014-09-20 | 2014-09-23 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | 02 | N | 310023544 | CHLORAMBUCIL |
| 310008037 | 310005188 | 1.77 | 83.3 | Disease modification (D) | 2014-10-04 | 2015-01-25 | DABRAFENIB + TRAMETINIB | 02 | null | 310023544 | CVP R |
| 310008038 | 310005188 | 1.55 | 40.1 | Palliative (P) | 2013-11-01 | 2013-11-02 | Niraparib | N | N | 310023544 | TOPOTECAN |
| 310008039 | 310008273 | null | 83 | Palliative (P) | 2016-09-02 | 2016-09-03 | CHOEP | N | N | 310023609 | BENDAMUSTINE |
| 310008040 | 310005192 | 1.8 | 58 | Palliative (P) | 2016-06-25 | 2016-06-27 | Bortezomib +/- Dexamethasone | 2 | null | 310023616 | AXI-STS TRIAL |
| 310008041 | 310008274 | null | null | Curative (C) | 2015-10-10 | 2015-11-02 | CETUXIMAB | N | N | 310023616 | TRIPLE INTRATHECAL |
| 310008042 | 310008274 | 1.63 | null | Palliative (P) | 2016-10-11 | 2016-10-26 | ICON8 TRIAL | null | null | 310023616 | METHOTREXATE |
| 310008043 | 310005193 | 1.6 | 81.8 | Curative (C) | 2017-09-12 | 2017-09-15 | Capecitabine | 02 | N | 310023631 | CAPECITABINE |
| 310008044 | 310005193 | 1.56 | 66.2 | Curative (C) | null | 2013-11-06 | Trabectedin | 02 | N | 310023631 | TEMOZOLOMIDE |
| 310008045 | 310005193 | 1.69 | null | Palliative (P) | 2014-06-17 | 2014-07-01 | Capecitabine + Oxaliplatin 21day | N | N | 310023631 | ECF |
| 310008046 | 310005194 | 1.67 | 64.4 | Disease modification (D) | 2016-06-19 | 2016-06-21 | Bortezomib + MELPHALAN | 02 | N | 310023659 | MITOMYCIN |
| 310008047 | 310005194 | 0 | 69.6 | Neo-adjuvant (N) | 2015-07-20 | 2015-08-23 | IVE-R | N | N | 310023659 | CVP |
| 310008048 | 310005194 | 1.64 | 109.9 | null | 2014-12-12 | 2014-12-17 | BCG Intravesical | N | N | 310023659 | REGORAFENIB |
| 310008050 | 310005197 | 1.62 | null | Adjuvant (A) | 2014-03-14 | 2014-03-17 | DACARBAZINE + GEMCITABINE | N | N | 310023746 | TRASTUZUMAB |
| 310008051 | 310009914 | null | 69.7 | Adjuvant (A) | 2014-03-29 | 2014-04-08 | Trabectedin | 2 | N | 310023772 | BEVACIZUMAB + CAPECITABINE |
| 310008052 | 310009914 | 1.8 | 62 | Palliative (P) | 2013-01-08 | 2013-05-05 | Oxaliplatin + Modified de Gramont | N | N | 310023772 | ECX |
| 310008053 | 310009914 | 1.67 | 62.45 | Palliative (P) | 2018-04-20 | 2018-04-28 | TOPOTECAN | 02 | null | 310023772 | DOXORUBICIN |
| 310008054 | 310005198 | 1.54 | 53 | Palliative (P) | 2015-10-29 | 2016-09-17 | CVD | 2 | N | 310023781 | BCG |
| 310008055 | 310005198 | 1.6 | 82.25 | Palliative (P) | 2014-07-20 | 2014-07-30 | BEP 5 Day | N | N | 310023781 | CETUXIMAB |
| 310008056 | 310005199 | 1.66 | 64 | Palliative (P) | 2017-07-12 | 2017-07-26 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | N | N | 310023798 | IFOSFAMIDE |
| 310008057 | 310005199 | 1.55 | 53.6 | Palliative (P) | 2016-08-24 | 2016-09-13 | ECX | N | N | 310023798 | PEMETREXED |
| 310008058 | 310005199 | 0 | null | Curative (C) | 2017-09-24 | 2017-09-25 | CHOEP | null | null | 310023798 | GEMCITABINE + OXALIPLATIN |
| 310008060 | 310005201 | 1.62 | null | Curative (C) | 2018-04-30 | 2018-05-04 | INTERFERON | 2 | N | 310023826 | ECF |
| 310008061 | 310005202 | null | 67 | Palliative (P) | 2015-07-01 | 2015-07-13 | Doxorubicin + Olaratumab | null | null | 310023832 | BCG |
| 310008062 | 310005203 | 0 | 87 | Neo-adjuvant (N) | 2015-04-13 | 2015-04-26 | CISPLATIN + VINORELBINE + RT | N | N | 310023862 | CISPLATIN + FLUOROURACIL |
| 310008063 | 310005203 | 1.7 | 50 | Palliative (P) | 2014-03-31 | 2014-03-31 | Cyclophosphamide + Topotecan | 02 | N | 310023862 | SPIRE TRIAL |
| 310008064 | 310005203 | 0 | null | null | 2018-03-19 | 2018-04-03 | Doxorubicin 75mg/m2 | N | N | 310023862 | VINCRISTINE |